Neurocrine Biosciences (NBIX): Director filed to sell ~$2.15M
GEORGE MORROW, Director at Neurocrine Biosciences, filed to sell ~$2.15M of Neurocrine Biosciences shares.
- ~$2.15M
- planned to sell · 15K shares, around Nov 2, 2026
- Planned for
- Nov 2, 2026
- Notice filed
- Nov 2, 2026
What stands out in this filing
- The planned sale is 0.01% of the company's shares outstanding, as stated on the notice.
- How the shares were acquired, per the notice: Exercise of Stock Options.
- The notice says the shares were received as pay (stock awards or options).
- Broker named on the notice: Morgan Stanley Smith Barney LLC Executive Financial Services.
- Remarks on the notice: The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale. .
- A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 28, 2026, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc. (the “Company”) appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026 (the “Transition Date”).”
- Oct 15, 20265% stakeJPMORGAN CHASE & CO. reported a passive stake (13G) of 5.2%
- Oct 30, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
- Oct 30, 2026InsiderDirector sold ~$45K of NBIX shares in the open market
- Nov 2, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 2, 2026Insider · 1 personInsiders: 3 sales (~$1.1M)
What came next
- Nov 3, 2026Insider · 1 personInsiders: 8 sales (~$1.2M)
- Nov 17, 2026Insider · 1 personInsiders: 4 sales (~$2.5M)
How to read SEC Form 144
Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.
Full guide: What is an SEC Form 144?
What else is on file for Neurocrine Biosciences
For Neurocrine Biosciences, OQRO holds 20 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NBIX page.
How this filing works
Explore the data
Common questions
Which Neurocrine Biosciences (NBIX) insider traded, and how much?
GEORGE MORROW, Director at Neurocrine Biosciences, filed to sell ~$2.15M of Neurocrine Biosciences shares. 15K shares, Form 144 notice of a planned sale.
When did it happen, and when was it made public?
Planned for: Nov 2, 2026. Notice filed: Nov 2, 2026.
What stands out in this filing?
The planned sale is 0.01% of the company's shares outstanding, as stated on the notice. How the shares were acquired, per the notice: Exercise of Stock Options. The notice says the shares were received as pay (stock awards or options).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Neurocrine Biosciences recently?
For Neurocrine Biosciences, OQRO holds 20 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the NBIX page.
Does this mean NBIX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Neurocrine Biosciences
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 144Nov 17, 2026
- SEC Form 144Nov 10, 2026
Everything OQRO holds on this company is on its NBIX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
